Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Multiple Sclerosis | Emerging Therapies | Zinbryta (daclizumab) | US | Wave 1 | 2016
Multiple Sclerosis | Emerging Therapies | Zinbryta | US is a three-wave series that tracks the introduction of Zinbryta for the treatment of multiple sclerosis (MS). The series is based on primary…
Multiple Myeloma | Emerging Therapies | Darzalex/Empliciti (Wave 2) | US | 2016
This three-wave syndicated research series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Emerging Therapies | Venclexta (venetoclax) | US | Wave 1 | 2016
LaunchTrends: Venclexta (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic…
Multiple Sclerosis | Emerging Therapies | Lemtrada (alemtuzumab) | US | Wave 4 | 2016
LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved to treat…
Malignant Melanoma | Emerging Therapies | Keytruda (pembrolizumab) | US | Wave 3 | 2015
LaunchTrends: Keytruda Wave 3 (US) is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the malignant melanoma drug…
